Endonovo Therapeutics Files Continuation Patent for Producing Adult Stem Cell 
LOS ANGELES, CA -- (Marketwired) -- 06/29/16 --  Endonovo
Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a
developer of bioelectronic devices and medicines, announced today
that it has filed a continuation patent, titled "Biological Molecules
Produced by Electromagnetically Stimulating Living Mammalian Cells."
Endonovo's patent filing covers a process for the production of the
adult stem cell secretome and its corresponding administration as a
next generation fully human biologic. 
This patent filing is a continuation of the prior announcement on
March 30, 2016.
Adult stem cells, such as Mesenchymal Stem Cells ("MSCs") isolated
from tissues, including bone marrow and the human umbilical cord
release a plethora of cytokines, interleukins, prostaglandins, and
growth factors, referred to collectively as the secretome. 
Many studies have ascertained and continue to clarify that the
therapeutic potential of adult stem cells is linked to their ability
to secrete therapeutic proteins and other molecules. However, human
cells typically secrete very low concentrations of these therapeutic
cytokines and growth factors and have required the use of recombinant
DNA technology to develop them as biologics.
According to Thomson Reuters, the biologics sector is set for an
unprecedented level of activity as U.S. companies have rapidly
increased their development of biologics during the past five years.
The market for next-generation biologics is estimated to reach a
value of $30 billion by 2024, according to Visiongain. These
next-generation biologics will seek to address shortcomings in
current therapies, including inconvenient dosing and potential
Endonovo CEO, Alan Collier commented, "We are largely looking at
adult stem cells as tiny drug factories capable of producing the most
complex and hard to produce drugs known as biologics." 
Mr. Collier went on to say, "One of the benefits of our approach in
using the secretome as a next generation fully human biologic is that
it is much easier to manufacture than conventional biologics
manufactured by synthetic or recombinant DNA technology, which could
result in better outcomes
 for patients and lower costs."
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is an innovative biotechnology company
developing bioelectronic devices and therapies for regenerative
medicine. Endonovo's Immunotronics(TM) platform is a non-invasive,
non-implantable bioelectronic device for treating/preventing vital
organ failure through the reduction of inflammation, cell death and
the promotion of regeneration. Endonovo's Cytotronics(TM) platform
provides for a method of expanding and manipulating cells using
simulated microgravity and Time-Varying Electromagnetic Fields
(TVEMF) for tissue engineering and cell therapies. The Company's
initial concentration is on the treatment of acute and chronic
inflammatory conditions of the liver using its proprietary
Immunotronics(TM) platform.
Safe Harbor Statement
This press release contains information that constitutes
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
All statements, trends, analysis, and other information contained in
this press release including words such as "anticipate," "believe,"
"plan," "estimate," "expect," "intend," and other similar expressions
of opinion, constitute forward-looking statements. Any such
forward-looking statements involve risks and uncertainties that could
cause actual results to differ materially from any future results
described within the forward-looking statements. Risk factors that
could contribute to such differences include those matters more fully
disclosed in the Company's reports filed with the Securities and
Exchange Commission. The forward-looking information provided herein
represents the Company's estimates as of the date of the press
release, and subsequent events and developments may cause the
Company's estimates to change. The Company specifically disclaims any
obligation to update the forward-looking information in the future.
Therefore, this forward-looking information should not be relied upon
as representing the Company's estimates of its future financial
performance as of any date subsequent to the date of this press
Investor Relations Contact: 
Endonovo Therapeutics, Inc. 
Mr. Steven Barnes
Senior Vice President of Investor Relations 
(800) 701-1223, Ext. 108
Source: Endonovo Therapeutics, Inc.
Investors: Sign Up for Email Alerts on Endonovo